564 related articles for article (PubMed ID: 34459681)
21. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.
Hashmi H; Hansen DK; Peres LC; Puglianini OC; Freeman C; De Avila G; Sidana S; Shune L; Sborov DW; Davis J; Wagner C; Kocoglu MH; Atrash S; Voorhees P; Simmons G; Ferreri C; Kalariya N; Anderson LD; Afrough A; Dima D; Khouri J; McGuirk J; Locke F; Baz R; Patel KK; Alsina M
Haematologica; 2024 May; 109(5):1514-1524. PubMed ID: 37855036
[TBL] [Abstract][Full Text] [Related]
22. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
[TBL] [Abstract][Full Text] [Related]
23. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
Ferment B; Arnulf B
Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.
Chen W; Wang Y; Qi K; Shi M; Cao J; Bhansali R; Wang X; Liu Y; Li H; Zhang H; Yan Z; Sang W; Cheng H; Zhu F; Sun H; Li D; Jing G; Zheng J; Li Z; Xu K
Transplant Cell Ther; 2021 Mar; 27(3):273.e1-273.e5. PubMed ID: 33781540
[TBL] [Abstract][Full Text] [Related]
25. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
Yan L; Qu S; Shang J; Shi X; Kang L; Xu N; Zhu M; Zhou J; Jin S; Yao W; Yao Y; Chen G; Chang H; Zhu X; Yu L; Wu D; Fu C
Cancer Med; 2021 Jan; 10(2):563-574. PubMed ID: 33356013
[TBL] [Abstract][Full Text] [Related]
26. Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function.
He SL; Cheng YH; Wang D; Xu ML; Que YM; Xu YJ; Ma LM; Li CR; Zhou JF
Curr Med Sci; 2021 Jun; 41(3):474-481. PubMed ID: 34169427
[TBL] [Abstract][Full Text] [Related]
27. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
[TBL] [Abstract][Full Text] [Related]
28. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
Ma T; Shi J; Liu H
Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
[TBL] [Abstract][Full Text] [Related]
29. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.
Xu J; Ming X; Wang C; Xu B; Xiao Y
Medicine (Baltimore); 2021 May; 100(18):e25784. PubMed ID: 33950974
[TBL] [Abstract][Full Text] [Related]
30. [Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy].
Cui R; Li P; Li Q; Mu J; Jiang YL; Jiang YY; Deng Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):502-507. PubMed ID: 34384157
[No Abstract] [Full Text] [Related]
31. Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial.
Asherie N; Kfir-Erenfeld S; Avni B; Assayag M; Dubnikov T; Zalcman N; Lebel E; Zimran E; Shaulov A; Pick M; Cohen Y; Avivi I; Cohen C; Gatt ME; Grisariu S; Stepensky P
Haematologica; 2023 Jul; 108(7):1827-1839. PubMed ID: 36200421
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.
Reyes KR; Huang CY; Lo M; Arora S; Chung A; Wong SW; Wolf J; Olin RL; Martin T; Shah N; Banerjee R
Transplant Cell Ther; 2023 Jun; 29(6):350-355. PubMed ID: 36933659
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma.
Costa BA; Flynn J; Nishimura N; Devlin SM; Farzana T; Rajeeve S; Chung DJ; Landau HJ; Lahoud OB; Scordo M; Shah GL; Hassoun H; Maclachlan K; Hultcrantz M; Korde N; Lesokhin AM; Shah UA; Tan CR; Giralt SA; Usmani SZ; Nath K; Mailankody S
Blood Cancer J; 2024 May; 14(1):84. PubMed ID: 38802346
[TBL] [Abstract][Full Text] [Related]
34. An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously.
Wang Q; Wei R; Guo S; Min C; Zhong X; Huang H; Cheng Z
Cancer Gene Ther; 2024 Mar; 31(3):420-426. PubMed ID: 38102463
[TBL] [Abstract][Full Text] [Related]
35. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
Zhao WH; Liu J; Wang BY; Chen YX; Cao XM; Yang Y; Zhang YL; Wang FX; Zhang PY; Lei B; Gu LF; Wang JL; Yang N; Zhang R; Zhang H; Shen Y; Bai J; Xu Y; Wang XG; Zhang RL; Wei LL; Li ZF; Li ZZ; Geng Y; He Q; Zhuang QC; Fan XH; He AL; Zhang WG
J Hematol Oncol; 2018 Dec; 11(1):141. PubMed ID: 30572922
[TBL] [Abstract][Full Text] [Related]
36. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC
J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447
[TBL] [Abstract][Full Text] [Related]
37. Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma.
Reyes KR; Liu YC; Huang CY; Banerjee R; Martin T; Wong SW; Wolf JL; Arora S; Shah N; Chari A; Chung A
Blood Adv; 2024 May; 8(9):2207-2216. PubMed ID: 38429087
[TBL] [Abstract][Full Text] [Related]
38. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
39. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.
Zhang Q; Zu C; Jing R; Feng Y; Zhang Y; Zhang M; Lv Y; Cui J; Zhou L; Meng Y; Wang L; Cen Z; Chang AH; Hu Y; Huang H
Front Immunol; 2023; 14():1125357. PubMed ID: 37215107
[TBL] [Abstract][Full Text] [Related]
40. An Assessment of the Effectiveness and Safety of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma Patients with Relapsed or Refractory Disease: A Systematic Review and Meta-Analysis.
Pereira R; Bergantim R
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
